What is the recommended diagnostic work‑up and first‑line pharmacologic and non‑pharmacologic management for an adult who suspects they have attention‑deficit/hyperactivity disorder?

Adult ADHD: Diagnostic Work-Up and First-Line Management

For adults suspecting ADHD, begin with a comprehensive clinical interview documenting childhood-onset symptoms (before age 12) that cause current functional impairment across multiple settings, then initiate long-acting stimulant medication (methylphenidate or amphetamine) as first-line pharmacotherapy, combined with cognitive behavioral therapy when available. 1, 2, 3

---

Diagnostic Work-Up

Essential Clinical Interview Components

Establish childhood onset: Document at least 6 symptoms of inattention and/or hyperactivity-impulsivity present before age 12 that have persisted into adulthood. 4, 3 The diagnosis requires symptoms causing functional impairment in at least two settings (work, home, social). 3, 5

Core inattentive symptoms to assess:

• Careless mistakes and difficulty sustaining attention
• Poor listening and failure to follow through on tasks
• Disorganization and avoidance of sustained mental effort
• Losing things, easy distractibility, forgetfulness 4

Core hyperactive-impulsive symptoms to assess:

• Fidgeting, inability to remain seated, restlessness
• Excessive talking, blurting answers, difficulty waiting turn
• Intrusiveness and interrupting others 4

Critical pitfall: Adults with ADHD are unreliable reporters of their own behaviors—always obtain collateral information from family members, partners, or close contacts to verify childhood symptoms and current functional impairment. 1 Review school records when available. 6

Validated Assessment Tools

Use standardized instruments to quantify symptoms and functional impairment:

• Adult ADHD Self-Report Scale (ASRS) for symptom screening (3-5 minutes) 3, 6
• Conners Adult ADHD Rating Scales for comprehensive evaluation 3

These tools facilitate diagnosis but do not replace clinical judgment. 3, 6

Differential Diagnosis and Comorbidity Screening

Screen for conditions that mimic or co-occur with ADHD (present in 80% of adults with ADHD): 5

• Mood disorders: Depression (unipolar/bipolar), anxiety, stress-related disorders 3, 5
• Substance use disorders: Very common, either as self-medication or consequence of impulsivity 5
• Personality disorders: Especially borderline and antisocial 5
• Sleep disorders: Restless leg syndrome, hypersomnolence (may share pathophysiology with ADHD) 5

Before initiating treatment, screen for personal or family history of bipolar disorder, mania, or hypomania. 4 Untreated bipolar disorder can be worsened by stimulants.

Pre-Treatment Cardiovascular Assessment

Obtain detailed personal and family cardiac history, specifically asking about:

• Sudden cardiac death in relatives <50 years old
• Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, Long QT syndrome
• Unexplained syncope, seizures, chest pain, or palpitations 1

Measure baseline blood pressure and pulse. 1 If cardiac risk factors are present, obtain ECG and consider cardiology referral before starting medication. 1

---

First-Line Pharmacologic Management

Stimulant Medications (First-Line)

Long-acting stimulant formulations are strongly preferred over immediate-release preparations due to superior medication adherence, consistent all-day symptom control, lower rebound risk, and reduced diversion potential. 1, 2

Amphetamine-based stimulants demonstrate superior efficacy in adults compared to methylphenidate (effect size -0.79 vs -0.49), with 70-80% response rates when properly titrated. 1, 2, 3

Recommended First-Line Options:

Lisdexamfetamine (Vyvanse):

• Start 20-30 mg once daily in morning
• Titrate by 10-20 mg weekly
• Target dose: 50-70 mg daily (maximum)
• Prodrug formulation reduces abuse potential 1, 2

Mixed amphetamine salts extended-release (Adderall XR):

• Start 10 mg once daily in morning
• Titrate by 5 mg weekly
• Target dose: up to 50 mg maximum 1

Methylphenidate extended-release (Concerta):

• Start 18 mg once daily in morning
• Titrate by 18 mg weekly
• Target dose: 36-72 mg daily (maximum)
• OROS delivery system is tamper-resistant 1, 2

Titration Protocol:

Increase dose weekly by 5-10 mg until symptoms resolve or maximum tolerated dose is reached. 1, 2 Do not calculate dose based on body weight—use systematic titration to achieve symptom control. 1 Maximum daily doses: 40 mg for amphetamine salts, 60 mg for methylphenidate. 1

Common pitfall: Stopping titration prematurely. Many patients require doses at the higher end of the therapeutic range for optimal response. 1, 2

Monitoring During Titration (First 4-6 Weeks):

• Weekly: Blood pressure, pulse, ADHD symptom rating scales (patient and informant), sleep quality, appetite 1
• Assess functional improvement across work, home, and social settings 1

Maintenance Monitoring:

• Monthly initially, then quarterly once stable 1
• Continue blood pressure and pulse checks at each visit 1
• Track weight (appetite suppression common) 1

Common Adverse Effects:

• Appetite suppression and weight loss
• Sleep disturbances (insomnia, delayed sleep onset)
• Mild cardiovascular effects: 1-2 bpm heart rate increase, 1-4 mmHg blood pressure increase 1
• Anxiety (monitor closely, does not contraindicate use) 1

Contraindications: Active stimulant abuse, symptomatic cardiovascular disease, uncontrolled hypertension. 1

---

Non-Stimulant Medications (Second-Line)

Reserve non-stimulants for patients who:

• Failed ≥2 adequate stimulant trials
• Experience intolerable stimulant side effects
• Have active substance use disorder
• Have comorbid anxiety/depression requiring concurrent treatment 1, 2, 3

Atomoxetine (Strattera) - FDA-Approved for Adults:

Dosing:

• Start 40 mg daily
• Increase after minimum 3 days to target 80 mg daily
• May increase to maximum 100 mg after 2-4 additional weeks if suboptimal response 4
• Can be taken as single morning dose or divided (morning and late afternoon/evening) 4

Key characteristics:

• Effect size ~0.7 (compared to stimulants ~1.0) 1, 2, 4
• Requires 6-12 weeks for full therapeutic effect (median 3.7 weeks) 1, 2, 4
• Provides 24-hour coverage 1, 2
• No abuse potential (non-controlled substance) 1, 2
• FDA black-box warning for suicidal ideation—baseline and regular screening mandatory 1

Extended-Release Guanfacine (Intuniv):

• Start 1 mg nightly (evening dosing preferred due to sedation)
• Titrate by 1 mg weekly to target 0.05-0.12 mg/kg/day (maximum 7 mg)
• Effect size ~0.7, full effect in 2-4 weeks 1, 2
• Particularly useful for comorbid sleep disturbances, anxiety, or tics 1
• Decreases heart rate and blood pressure (beneficial for cardiovascular concerns) 1

Extended-Release Clonidine (Kapvay):

• Similar dosing and characteristics to guanfacine
• Effect size ~0.7 1, 2

Bupropion:

• Modest ADHD activity (effect size ~0.7)
• Consider when depression is comorbid 1, 3
• Second-line alternative to atomoxetine 1

Viloxazine Extended-Release (Qelbree):

• Serotonin-norepinephrine modulating agent
• Demonstrated efficacy in pediatric trials; limited adult data 7, 1
• Emerging option with favorable tolerability 1

---

First-Line Non-Pharmacologic Management

Cognitive Behavioral Therapy (CBT)

CBT is the most extensively studied and effective psychotherapy for adult ADHD, focusing on:

• Time management and organization skills
• Planning and prioritization strategies
• Adaptive behavioral skills development 1

CBT is most effective when combined with medication rather than used as monotherapy. 1, 8 For moderate-to-severe ADHD, medication alone has stronger immediate effects on core symptoms than behavioral therapy alone. 7

Psychoeducation and Self-Management

Provide comprehensive psychoeducation about:

• ADHD as a chronic neurodevelopmental disorder requiring ongoing management 8, 9, 5
• Expected treatment course and importance of adherence 5
• Strategies for managing symptoms in daily life 5

Coaching and supportive problem-directed therapy are useful adjuncts to medication management. 10

Mindfulness-Based Interventions

Mindfulness-based interventions show increasing evidence for managing adult ADHD, particularly helping with:

• Inattention symptoms
• Emotion regulation
• Executive function
• Quality of life 1

---

Treatment Algorithm Summary

Step 1: Initiate long-acting amphetamine-based stimulant (lisdexamfetamine or Adderall XR) with weekly titration. 1, 2

Step 2: If inadequate response to first stimulant class, trial methylphenidate extended-release (approximately 40% respond to both classes, 40% to only one). 1, 2

Step 3: If both stimulant classes fail or are contraindicated, trial atomoxetine (allow 6-12 weeks for full effect). 1, 2

Step 4: If atomoxetine insufficient, consider extended-release guanfacine or clonidine (allow 2-4 weeks for treatment effects). 1

Throughout: Combine pharmacotherapy with CBT and psychoeducation for optimal functional outcomes. 1, 5

---

Critical Clinical Pitfalls to Avoid

• Do not use immediate-release or "as-needed" stimulants—ADHD requires consistent daily symptom control across all settings. 1
• Do not assume patient preference against daily medication is immutable—education about long-acting formulations and risks of untreated ADHD often resolves concerns. 1
• Do not switch stimulant classes after inadequate trial—ensure maximum tolerated dose is reached before declaring treatment failure. 1, 2
• Do not prescribe stimulants to adults with active substance abuse without careful consideration—atomoxetine or guanfacine are safer alternatives. 1, 4
• Do not delay ADHD treatment due to comorbid mood symptoms—untreated ADHD worsens functional impairment and can amplify anxiety/depression. 7, 1

---

Long-Term Management Considerations

ADHD is a chronic condition requiring extended treatment. 8, 9, 5 A 7-week randomized discontinuation study demonstrated that patients on methylphenidate >2 years experienced significant symptom worsening when medication was stopped. 1

Periodically reassess whether continued treatment remains necessary, but do not discontinue effective ADHD treatment solely due to concerns about "taking medication forever"—untreated ADHD is associated with increased risk of accidents, substance abuse, criminality, and functional impairment. 1, 9

Establish systematic monitoring schedule:

• Blood pressure and pulse at each medication adjustment
• Periodic cardiovascular assessments during stable long-term treatment 1